

University of Groningen

Effects of Discontinuing Methylphenidate on Strengths and Difficulties, Quality of Life and Parenting Stress

Matthijssen, Anne-Flore M.; Dietrich, Andrea; Bierens, Margreet; Deters, Renee Kleine; van de Loo-Neus, Gigi H. H.; van den Hoofdakker, Barbara J.; Buitelaar, Jan K.; Hoekstra, Pieter J.

Published in:
Journal of Child and Adolescent Psychopharmacology

DOI:
[10.1089/cap.2019.0147](https://doi.org/10.1089/cap.2019.0147)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Matthijssen, A-F. M., Dietrich, A., Bierens, M., Deters, R. K., van de Loo-Neus, G. H. H., van den Hoofdakker, B. J., Buitelaar, J. K., & Hoekstra, P. J. (2019). Effects of Discontinuing Methylphenidate on Strengths and Difficulties, Quality of Life and Parenting Stress. *Journal of Child and Adolescent Psychopharmacology*, 30(3), 159-165. <https://doi.org/10.1089/cap.2019.0147>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Effects of Discontinuing Methylphenidate on Strengths and Difficulties, Quality of Life and Parenting Stress

Anne-Flore M. Matthijssen, MSc,¹ Andrea Dietrich, PhD,¹ Margreet Bierens, MSc,² Renee Kleine Deters, MSc,¹ Gigi H.H. van de Loo-Neus, MD,² Barbara J. van den Hoofdakker, PhD,^{1,3} Jan K. Buitelaar, MD, PhD,⁴ and Pieter J. Hoekstra, MD, PhD¹

Abstract

Objectives: To study the effects of discontinuation of long-term methylphenidate use on secondary outcome measures of strengths and difficulties, quality of life (QoL), and parenting stress.

Methods: Ninety-four children and adolescents aged 8 to 18 years who had used methylphenidate for over 2 years were randomly assigned to double-blind continuation of treatment for 7 weeks (36 or 54 mg extended release methylphenidate) or to gradual withdrawal over 3 to 4 weeks placebo. We used mixed models for repeated measures to investigate effects on parent, teacher, and child ratings of hyperactivity/inattention and comorbid symptoms with the Strengths and Difficulties Questionnaire (SDQ), investigator- and teacher-rated oppositional symptoms (Conners Teacher Rating Scale-Revised: short form [CTRS-R:S]), and parent-rated aggression with the Retrospective Modified Overt Aggression Scale. QoL was assessed with the Revised Questionnaire for Children and Adolescents to record health-related quality of life and parenting stress with the Nijmegen Parental Stress Index.

Results: Hyperactivity/inattention scores from the parent- and teacher-rated SDQ (difference in mean change over time of respectively: -1.1 [95% confidence interval, CI, -2.0 to -0.3]; $p=0.01$; -2.9 [95% CI -2.9 to -0.7 ; $p=0.01$]) and oppositional scores of the teacher-rated CTRS-R:S (difference in mean change -1.9 95% CI $[-3.1$ to -0.6 ; $p<0.01$]) deteriorated to a significantly larger extent in the discontinuation group than in the continuation group. We did not find effects on other symptom domains, aggression, QoL, and parenting stress after discontinuation of methylphenidate.

Conclusion: Our study suggests beneficial effects of long-term methylphenidate use beyond 2 years for oppositional behaviors in the school environment. Similarly, beneficial effects were found on hyperactivity-inattention symptoms as rated by parent and teacher scales, confirming our primary study on investigator ratings of attention-deficit/hyperactivity disorder. However, discontinuation of methylphenidate did not appear to have impact on other comorbid problems or aspects of the child's or parental functioning.

Keywords: methylphenidate, ADHD, long-term benefits, parenting stress, quality of life, aggression

Introduction

METHYLPHENIDATE IS THE FIRST-LINE pharmacological treatment for children with attention-deficit/hyperactivity disorder (ADHD) (NICE guideline, 2018) and its short-term efficacy for reducing ADHD symptoms is well established (Cortese et al., 2018). ADHD symptoms are often accompanied by comorbid symptoms such as oppositional behaviors, aggression, mood problems, anxiety, and by impaired social functioning (Biederman, 2005;

Ros and Graziano, 2018). Besides, patients with ADHD often experience a lower quality of life (QoL) (Lee et al., 2016; Mulraney et al., 2017). ADHD treatment should therefore not only result in symptomatic improvement, but also increase the child's QoL, as acknowledged in the European Medicines Agency guidance on outcomes in clinical studies (European Medicines Agency, 2010).

There is evidence that psychostimulants including methylphenidate have a moderate-to-large short-term (i.e., up to 16 weeks) effect on the management of oppositional behavior, conduct problems, and

¹Department of Child and Adolescent Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

²Karakter Child and Adolescent Psychiatry Center Nijmegen, Nijmegen, The Netherlands.

³Department of Clinical Psychology and Experimental Psychopathology, University of Groningen, Groningen, The Netherlands

⁴Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.

Funding: This study was funded by The Netherlands Organization for Health Research and Development (ZonMw); Grant No. 836011014.

Clinical Trial Registration: <https://www.trialregister.nl/trial/5120>

aggression in children and adolescents with ADHD with or without comorbid oppositional-deviant disorder (ODD) or conduct disorder (Pringsheim et al., 2015). Furthermore, systematic reviews concluded that there may be a short-term positive effect of ADHD medication on QoL in children and adolescents (Coghill, 2010; Coghill et al., 2017). However, the effect sizes are smaller than seen for ADHD symptoms and almost exclusively based on studies examining atomoxetine.

ADHD in children may also affect the well-being of their parents. Several studies have shown that parents of children with ADHD experience more parenting stress than parents of typically developing children (Herrerias et al., 2001; Brandt-Dominicus, 2005; Poulton et al., 2013; Dey et al., 2018) perhaps resulting from the increased demands of caretaking, economical costs of medical care, role dissatisfaction, increased levels of parental frustration, marital discord, or divorce (Laugesen et al., 2016). The parenting stress level that parents experience is directly related to the number of ADHD symptoms in their children, according to a range of studies (Deault, 2010; Graziano et al., 2011; Haack et al., 2016). Moreover, an open label study suggested that methylphenidate use may decrease parenting stress and depression, with improvements in parenting mood and stress being associated with the decrease in ADHD symptom severity (Hwang et al., 2013).

Benefits of methylphenidate have been based on short-term studies; its long-term benefits remain unclear (Coghill, 2019; Cortese, 2019; Swanson, 2019). Nevertheless, 60% of the children who started stimulants continue to use these beyond 2 years (Zetterqvist et al., 2013; Beau-Lejdstrom et al., 2016). In our recently published placebo-controlled double-blind discontinuation trial, we saw that methylphenidate remains effective after 2 years of use, with regard to the investigator-rated ADHD rating scale (ADHD-RS) as our primary outcome measure (Matthijssen et al., 2019). In this study, we included children and adolescents who had been using methylphenidate for over 2 years. Here, we aimed to study the effects of discontinuing methylphenidate on secondary outcome measures based on parent, teacher, and/or child reports of hyperactivity/inattention and comorbid symptoms such as oppositional-deviant behavior, the child's QoL, and parenting stress. Given the short-term benefits of methylphenidate on oppositional behavior, conducts problems, aggression, QoL, and parenting stress, we hypothesized that discontinuation of methylphenidate after long-term use would result in deterioration in these areas.

Methods

Participants

Participants were children between 8 and 18 years of age who had been using methylphenidate for more than 2 years, in the form of extended release 36 or 54 mg/day during at least the last 4 weeks. To allow children who were originally not using 36 or 54 mg/day of extended-release methylphenidate to participate they could switch to one of these dosages, whichever was the closest to the dosage they were already using. We included children with an IQ over 70. Both parents and children who were 12 years and older provided written informed consent. For children under 12 years, the parents provided written informed consent, and the children oral assent, in accordance with Dutch medical ethical laws. On the consent forms parents could separately give permission to obtain teacher-ratings, which was optional. The study was approved by national and local institutional review board committees. More detailed information about inclusion criteria can be found in Matthijssen et al. (2019).

Design and interventions

Participants were randomly assigned in a 1:1 ratio to either continue active medication at the same maintenance dose for 7 weeks or to gradual withdrawal to placebo over a 3-week period followed by 4 weeks of complete placebo. We obtained ratings at baseline and after 7 weeks, or earlier in case of study drop out (i.e., at time of study drop out).

Outcomes

Strengths and difficulties. To investigate the effects of methylphenidate discontinuation on symptom domains, we used the parent-, teacher-, and child-reports (ages 11–16) of the Strengths and Difficulties Questionnaire (SDQ, Dutch version) (Van Widenfelt et al., 2003). The SDQ is a widely used, brief screening questionnaire, aimed at identifying behavioral and emotional problems in children, containing 25 items rated on a three-point scale ranging from “0 = not true” to “2 = very true.” It contains five subscales with each five items (range 0–10): (1) Emotional symptoms, (2) Conduct problems, (3) Hyperactivity/inattention, (4) Peer relationship problems, and (5) Prosocial behavior; and a Total score (sum score of the first four subscales, range 0–40).

To assess oppositional behavior in the school environment, we used the teacher-rated Oppositional subscale (range 0–15) of the Conners Teacher Rating Scale-Revised: short form (CTRS-R:S) (Conners et al., 1998). The CTRS-R:S is a 28-item, four-point Likert rating scale, ranging from “0 = not at all” to “3 = very often”, that contains items on ADHD and comorbid conditions.

To assess ODD symptoms, we used the investigator administered total score on the ODD rating scale (ODD-RS) *Diagnostic and Statistical Manual of Mental Disorders*, 5th ed. (DSM-5) (Hommersen et al., 2006). This is the adapted version of the ODD-RS DSM-IV, in accordance with the changes of ODD criteria introduced in the DSM-5 (American Psychiatric Association, 2013). The ODD-RS contains eight items scored on a four-point Likert scale, ranging from “0 = never” to “3 = very often”, and assesses ODD symptom severity (sum score range 0–24) over the past week.

Aggressive behavior was assessed by the parent-completed Retrospective Modified Overt Aggression Scale [R-MOAS, as used in Blader et al. (2009, 2010)]. Parents rated the weighted frequency of 16 aggressive behaviors across four areas over the past week: verbal aggression (range 0–20), physical aggression toward others (range 0–120), aggression toward oneself (range 0–90), and destruction or hostile misuse of property (range 0–60) on three- or four-point Likert scales ranging from “none or 0–1 times” to “5 times or more”. We used the total sum score of all subscales (range 0–290).

Quality of life. The parent- and child-rated Revised questionnaire for Children and adolescents to record health-related quality of life (KINDL-R) assesses children's QoL in six domains, namely Physical Well-Being, Emotional Well-Being, Self-Esteem, Friends, Family, and School (Ravens-Sieberer and Bullinger, 1998, 2000). It contains 30 items using a five-point Likert scale from “1 = never” to “5 = always”. The subscale scores range from 4 to 20 and the total score represents the sum of the subscales scores (range 24–120).

Parenting stress. The short version of the *Nijmegen Parental Stress Index* (NOSI-K, the Dutch version of the Parental Stress Index) (Brock de et al., 1992; Abidin, 2012), measures the amount of stress or pressure of several aspects within the context of parenting a child. It consists of 10 subscales assessing a parent (Competence, Attachment, Depression, Health, Adjustment, and Mood) and child

domain (Distractibility, Demanding, Positive Ratification, and Acceptance), and a total score. Parents score 25 items on a six-point Likert scale ranging from 1 = completely agree to 6 = completely disagree. In our study, we calculated a total score as the sum of the child domain subscales (range 14–84).

Randomization

For each dosage, the trial pharmacy made a separate computer-generated randomization list. The study medication for either continued active medication or discontinuation was dispensed in accordance with these lists. We used a block-randomization of six to establish even groups.

Statistical methods

We used the group \times time interaction of the mixed model for repeated measures to analyze differences in outcome measures from baseline to 7 weeks between both randomized groups, using group (continuation or discontinuation) and time point (baseline or 7 weeks) as fixed effects. An unstructured covariance matrix was used. Analyses were conducted on the full dataset, which included all participants who received at least one dose of the study drug. In those who had withdrawn from the study we used ratings that were obtained at the time of study termination. The significance threshold for all analyses was $p < 0.05$. We first conducted analyses on the total scores of the different outcome

measures and only if significant further analyzed the subscale scores, to reduce the number of tests where appropriate.

Results

Strengths and difficulties

Tables 1 and 2 indicate a significant effect of discontinuation on the parent- and teacher-rated SDQ total scores. Subsequent analyses on the SDQ subscales revealed significant differences between the discontinuation and continuation group in the level of mean change regarding the Hyperactivity/inattention subscale, both parent- and teacher-rated, but not on the other subscales. Thus, the Hyperactivity/inattention scores deteriorated to a significantly larger extent in the discontinuation group than in the continuation group.

Tables 1 and 2 also shows a significant difference regarding the teacher-rated CTRS-R:S Oppositional subscale between the discontinuation and continuation group in the level of mean change after 7 weeks from baseline, indicating that on average the teacher-rated Oppositional scores deteriorated to a significantly larger extent in the discontinuation group than in the continuation group. The result for investigator-rated oppositional symptoms by the ODD-RS reached marginal significance.

Lastly, we did not find significant differences in the level of mean change between the discontinuation and continuation groups between baseline and 7 weeks for the total score of the child-reported SDQ and parent-rated aggression by the R-MOAS (Tables 1 and 2).

TABLE 1. BASELINE SCORES OF PARENT-, TEACHER-, CHILD-, AND INVESTIGATOR-RATED SYMPTOM DOMAINS

Measure	Discontinuation			Continuation			
	Baseline	Mean	SE	95% CI	Mean	SE	95% CI
<i>Parent-rated</i>		n = 45			n = 46		
SDQ-parent							
Total score	13.8	0.84	12.2–15.5	15.7	0.82	14.1–17.4	
Emotional symptoms	2.4	0.31	1.8–3.1	3.1	0.32	2.4–3.7	
Conduct problems	2.7	0.26	1.6–2.7	2.6	0.28	2.0–3.1	
Hyperactivity/inattention	6.4	0.35	5.7–7.0	7.0	0.34	6.3–7.7	
Peer relations	2.3	0.32	1.7–3.0	3.1	0.32	2.5–3.8	
Prosocial behavior	7.6	0.33	6.9–8.2	6.8	0.32	6.2–7.4	
R-MOAS aggression	109.3	2.3	104.8–113.9	108.1	2.3	103.6–112.6	
<i>Teacher-rated</i>		n = 38			n = 40		
SDQ-teacher							
Total score	10.0	0.96	8.0–11.9	13.4	0.94	11.5–15.2	
Emotional symptoms	2.2	0.35	1.5–2.9	2.4	0.34	1.7–3.1	
Conduct problems	1.0	0.28	0.4–1.5	1.8	0.38	1.2–2.3	
Hyperactivity/inattention	4.6	0.46	3.7–5.5	5.8	0.45	4.9–6.7	
Peer relations	2.2	0.39	1.4–3.0	3.4	0.38	2.7–4.2	
Prosocial behavior	7.0	0.36	6.3–7.7	5.7	0.35	5.0–6.4	
CTRS-R:S-oppositional	7.2	0.52	6.1–8.2	8.1	0.51	7.1–9.1	
<i>Child-rated</i>		n = 38			n = 41		
SDQ-child							
Total score	13.0	0.78	11.5–14.6	14.5	0.75	13.0–16.0	
<i>Investigator-rated</i>		n = 47			n = 47		
ODD-RS	4.8	0.71	3.4–6.2	5.6	0.71	4.2–7.0	

CI, confidence interval; CTRS-R:S, Conners Teacher Rating Scale-Revised: short form; ODD-RS, Oppositional-Deviant Disorder Rating Scale; R-MOAS, Retrospective Modified Overt Aggression Scale; SDQ, Strengths and Difficulties Questionnaire; SE, standard error.

TABLE 2. CHANGE SCORES FROM BASELINE TO SEVEN WEEKS OF PARENT-, TEACHER-, CHILD- AND INVESTIGATOR-RATED SYMPTOM DOMAINS

Measure	Discontinuation				Continuation				Analysis			
	Mean	SE	95% CI	Mean	SE	95% CI	Δ Change between groups ^a	95% CI	F	df	p	
<i>Parent-rating</i>			n = 40			n = 45						
SDQ-parent												
Total score	14.0	0.87	12.3 to 15.8	13.8	0.83	12.2 to 15.5	-2.1	-4.0 to -0.2	4.92	90	0.03	
Emotional symptoms	2.4	0.33	1.7 to 3.0	2.4	0.32	1.8 to 3.0	-0.62	-1.4 to 0.1	2.79	90	0.10	
Conduct problems	2.2	0.26	1.6 to 2.7	2.0	0.25	1.5 to 2.5	0.10	-0.5 to 0.6	0.027	90	0.87	
Hyperactivity/inattention	7.1	0.34	6.5 to 7.8	6.6	0.33	6.0 to 7.3	-1.1	-2.0 to -0.3	6.54	90	0.01	
Peer relations	2.4	0.31	1.8 to 3.0	2.8	0.30	2.2 to 3.3	-0.43	-1.0 to 0.2	2.04	90	0.16	
Prosocial behavior	7.0	0.37	6.3 to 7.7	6.6	0.35	5.9 to 7.3	0.38	-0.4 to 1.1	0.97	90	0.33	
R-MOAS aggression	111.4	3.0	105.3 to 117.4	109.7	3.0	103.7 to 115.6	-0.52	-5.7 to 4.7	0.04	90	0.84	
<i>Teacher-rating</i>			n = 38			n = 37						
SDQ-teacher												
Total score	12.1	0.98	10.2 to 14.1	12.6	0.95	10.8 to 14.5	-2.9	-5.1 to -0.7	6.85	76	0.01	
Emotional symptoms	2.4	0.35	1.7 to 3.1	2.4	0.34	1.7 to 3.1	0.4	-0.4 to 1.1	0.97	76	0.57	
Conduct problems	1.4	0.27	0.8 to 1.9	1.8	0.28	1.2 to 2.3	-0.7	-1.3 to 0.1	3.40	76	0.07	
Hyperactivity/inattention	6.0	0.48	5.0 to 7.0	5.7	0.47	4.8 to 6.6	-1.5	-2.4 to -0.5	8.76	76	<0.01	
Peer relations	2.4	0.38	1.7 to 3.1	3.1	0.35	2.4 to 3.8	-0.6	-1.3 to 0.2	1.99	76	0.16	
Prosocial behavior	6.7	0.38	5.9 to 7.4	5.9	0.37	5.1 to 6.6	0.5	-0.3 to 1.4	1.46	76	0.23	
CTRS-R:S-oppositional	8.3	0.53	7.2 to 9.3	7.3	0.53	6.3 to 8.4	-1.9	-3.1 to -0.6	8.60	77	<0.01	
<i>Child-rating</i>			n = 35			n = 41						
SDQ-child												
Total score	11.6	0.86	9.9 to 13.3	12.4	0.81	10.8 to 14.0	-0.65	-2.9 to 1.6	0.32	77	0.57	
<i>Investigator-rating</i>			n = 47			n = 47						
ODD-RS	6.4	0.76	4.9 to 7.9	5.3	0.76	3.8 to 6.8	-1.9	-4.0 to 0.1	3.49	92	0.07	

^aIndicates the difference (Δ) in mean change from baseline to endpoint between the discontinued and continued treatment groups, including 95% CI by mixed models for repeated measurements analysis. CI, confidence interval; CTRS-R:S, Conners Teacher Rating Scale-Revised: short form; df, degrees of freedom; ODD-RS, Oppositional-Deviant Disorder Rating Scale; R-MOAS, Retrospective Modified Overt Aggression Scale; SDQ, Strengths and Difficulties Questionnaire; SE, standard error.

QoL and parenting stress

There were no significant differences in QoL between the discontinuation and continuation groups in the level of mean change between baseline and 7 weeks for the parent- and child-rated KINDL-R total score, nor for the parenting stress total score (child domain) measured with the NOSI-K (Table 3).

Discussion

We investigated the effects of discontinuing methylphenidate after more than 2 years of use on a number of broad symptom domains, QoL, and parenting stress. This was based on parent-, teacher-, child-, and investigator-rated outcome measures in a 7-week double-blind placebo-controlled discontinuation trial, as a follow-up to our initial study assessing investigator-rated ADHD symptoms as the primary outcome measure using the ADHD-RS (Zhang et al., 2005). In line with our previous results, we found long-term benefits of continued treatment with methylphenidate on the hyperactivity/inattention subscale of the parent- and teacher-rated SDQ. This supports sufficient sensitivity of the brief screening questionnaire SDQ pointing to the beneficial use of methylphenidate regarding the home and school environment.

We also found significantly deteriorated oppositional problems after discontinuation of methylphenidate as indicated by teacher-ratings, while deterioration of investigator-rated oppositional symptoms was marginally significant, as was deterioration of teacher-rated conduct problems. This is consistent with a meta-analysis of short-term efficacy studies (i.e., up to 16 weeks) of methylphenidate regarding oppositional behavior and conduct problems (Pringsheim et al., 2015). Still in contrast to this study, we did not find a significant effect of continued methylphenidate treatment on parent-rated aggression. A possible explanation for less evident findings regarding parent-ratings could be that teachers report a lower placebo response than parents do, as found in a recently published placebo-controlled

crossover trial with methylphenidate (Fageera et al., 2018). No effects of discontinuation were observed on child-rated symptoms, child- and parent-rated QoL, or parenting stress, suggesting that patients may be withdrawn from methylphenidate without deterioration of QoL, aggression, nor an increase in parenting stress. One should keep in mind, however, that we do not know to what extent participants in this study experienced these problems at the start of their methylphenidate treatment.

Strengths and limitations

A strength was the high ecological validity of the study, given the embedding in regular clinical care and the use of rating scales based on multiple informants. It should be noted, however, that the study had not been primarily powered to investigate changes other than ADHD symptoms. Therefore, it cannot be ruled out that a larger sample size would still indicate long-term benefits of methylphenidate use on certain comorbid symptoms, aggression, QoL, or parenting stress. Another limitation may be that the study reports on data assessed briefly after discontinuation of methylphenidate and that some measures, such as QoL, may have a longer latency to take effect. In future studies thus larger sample sizes and longer follow-up periods may be needed.

Conclusion

Our study indicates beneficial effects of long-term methylphenidate use on hyperactivity/inattention and oppositional behaviors. However, we did not find evidence for long-term benefits on other comorbid symptoms, QoL, or parenting stress. These latter results are in contrast with short-term effectiveness findings of methylphenidate.

Clinical Significance

This suggests that, in line with guidelines recommendations, there should be periodical assessments whether continued use of

TABLE 3. BASELINE SCORES AND CHANGE SCORES FROM BASELINE TO 7 WEEKS IN QUALITY OF LIFE (KINDL-R) AND PARENTING STRESS SCORES (NOSI-K)

Baseline	Discontinuation			Continuation								
	Mean	SE	95% CI	Mean	SE	95% CI						
KINDL-R parent-rating Total score	71.3											
			n = 45			69.7 to 72.8			n = 46			
KINDL-R child-rating Total score	70.6					68.9 to 72.3			n = 46			
			n = 45						n = 46			
NOSI-K parent-rating Total score (child domain)	35.4					31.1 to 39.6			n = 43			
			n = 42						n = 43			
Seven weeks	Mean	SE	95% CI	Mean	SE	95% CI	Δ Change between groups ^a	95% CI	F	df	p	
KINDL-R parent-rating Total score	71.0	0.73	69.5 to 72.4	69.5	0.72	68.0 to 70.9	-0.06	-2.1 to 2.0	0.003	89	0.95	
			n = 46			n = 47						
KINDL-R child-rating Total score	71.1	0.92	69.3 to 72.9	70.8	0.92	69.0 to 72.7	-1.35	-4.1 to 1.3	0.99	89	0.32	
			n = 46			n = 46						
NOSI-K parent-rating Total score (child domain)	37.4	2.3	32.9 to 41.9	35.2	2.3	30.7 to 39.6	-4.4	-9.1 to 0.4	3.4	83	0.07	
			n = 43			n = 41						

^aIndicates the difference (Δ) in mean change from baseline to endpoint between the discontinued and continued treatment groups, including 95% CI by mixed models for repeated measurements analysis.

CI, confidence interval; df, degrees of freedom; KINDL-R, Revised questionnaire for Children and adolescents to record health-related quality of life; NOSI-K, Nijmegen Parental Stress Index; SE, standard error.

methylphenidate is still needed in the individual child or adolescent by considering a temporary discontinuation. This may be done without negative consequences for QoL, parenting stress, or comorbid symptoms, beyond ADHD symptoms at home and school and oppositional symptoms at school. While our study suggests beneficial effects of long-term methylphenidate use regarding oppositional symptoms, it should be noted that nonpharmacological treatment (i.e., parent training) may also lead to long-term improvement of oppositional behavior (Hautmann et al., 2009; Högström et al., 2017; Döpfner et al., 2018).

Disclosures

Matthijssen, Hoekstra, Dietrich, Kleine Deters, and Bierens report no competing interests. van de Loo-Neus is and has been a member of Dutch ADHD guideline groups; is an advisor of the Dutch Knowledge Centre for Child and Adolescent Psychiatry. van den Hoofdakker receives royalties as one of the editors of “Sociaal Onhandig” (published by Van Gorcum), a Dutch book for parents that is being used in parent training for children with ADHD. Non-financial: developed and evaluates several Dutch parent training programs, without financial interests; is and has been a member of Dutch ADHD guideline groups; is an advisor of the Dutch Knowledge Centre for Child and Adolescent Psychiatry. Buitelaar has been in the past 3 years a consultant to/member of advisory board of/and/or speaker for Shire, Roche, Medice, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties.

References

- Abidin RR: Parenting Stress Index (4th ed). Lutz, FL: PAR; 2012.
- American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
- Beau-Lejdstrom R, Douglas I, Evans SJW, Smeeth L: Latest trends in ADHD drug prescribing patterns in children in the UK: Prevalence, incidence and persistence. *BMJ Open* 6:e010508, 2016.
- Biederman J: Attention-deficit/hyperactivity disorder: A selective overview. *Biol Psychiatry* 57:1215–1220, 2005.
- Blader JC, Pliszka SR, Jensen PS, Schooler NR, Kafantaris V: Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD. *Pediatrics* 126:e796–e806, 2010.
- Blader JC, Schooler, Nina R, Jensen PS, Pliszka SR, Kafantaris V: Adjunctive divalproex versus placebo for children with adhd and aggression refractory to stimulant monotherapy. *Am J Psychiatry* 166:1392–1401, 2009.
- Brandt-Dominicus JC. Multidisciplinary guideline ADHD [in Dutch]. 2005. <https://doi.org/10.1007/BF03059802> Accessed December 16, 2019.
- Brock de AJLL, Vermulst AA, Gerris JRM, Abidin RR: NOSI, manual experimental version [in Dutch]. Amsterdam: Pearson; 1992.
- Coghill D: The impact of medications on quality of life in attention-deficit hyperactivity disorder: A systematic review. *CNS Drugs* 24: 843–866, 2010.
- Coghill D: Debate: Are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? (For). *J Am Acad Child Adolesc Psychiatry* 58:938–939, 2019.
- Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A: Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. *Eur Child Adolesc Psychiatry* 26: 1283–1307, 2017.
- Conners CK, Sitarenios G, Parker JDA, Epstein JN: Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): Factor structure, reliability, and criterion validity. *J Abnorm Child Psychol* 26:279–291, 1998.
- Cortese S: Debate: Are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? *J Am Acad Child Adolesc Psychiatry* 58:936, 2019.
- Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A: Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. *Lancet Psychiatry* 5:727–738, 2018.
- Deault LC: A systematic review of parenting in relation to the development of comorbidities and functional impairments in children with attention-deficit/hyperactivity disorder (ADHD). *Child Psychiatry Hum Dev* 41:168–192, 2010.
- Dey M, Paz Castro R, Haug S, Schaub MP: Quality of life of parents of mentally-ill children: A systematic review and meta-analysis. *Epidemiol Psychiatr Sci* 2018. <https://doi.org/10.1017/S2045796018000409>.
- Döpfner M, Liebermann-Jordanidis H, Kinnen C, Hallberg N, Mokros L, Benien N, Mütsch A, Schürmann S, Wolff Metternich-Kaizman T, Hautmann C, Dose C: Long-term effectiveness of guided self-help for parents of children with ADHD in routine care—An observational study. *J Atten Dis* 2018. <https://doi.org/10.1177/1087054718810797>
- European Medicines Agency: Guideline on the clinical investigation of medicinal products for the treatment of attention-deficit/hyperactivity disorder (ADHD). 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/08/WC500095686.pdf Accessed December 16, 2019.
- Fageera W, Traicu A, Sengupta SM, Fortier ME, Choudhry Z, Labbe A, Grizenko N, Joober, R. Placebo response and its determinants in children with ADHD across multiple observers and settings: A randomized clinical trial. *Int J Methods Psychiatr Res* 27:1–10, 2018.
- Graziano PA, McNamara JP, Geffken GR, Reid A: Severity of children’s ADHD symptoms and parenting stress: A multiple mediation model of self-regulation. *J Abnorm Child Psychol* 39:1073–1083, 2011.
- Haack L, Villodas MT, Mcburnett K, Hinshaw S, Pffiffer L: Parenting Mediates symptoms and Impairment in Children with ADHD-inattentive type. *J Clin Child Adolesc Psychol* 45:155–166, 2016.
- Hautmann C, Hoijtink H, Eichelberger I, Hanisch C, Plck J, Walter D, Döpfner M: One-year follow-up of a parent management training for children with externalizing behaviour problems in the real world. *Behav Cogn Psychother* 37:379–396, 2009.
- Herrerias CT, Perrin JM, Stein MT: The child with ADHD: Using the AAP clinical practice guideline. *Am Fam Physician* 63:1803–1810, 2001.
- Högström J, Olofsson V, Özdemir M, Enebrink P, Stattin H: Two-year findings from a national effectiveness trial: Effectiveness of behavioral and non-behavioral parenting programs. *J Abnorm Child Psychol* 45:527–542, 2017.
- Hommersen P, Murray C, Ohan JL, Johnston C: Oppositional defiant disorder rating scale: Preliminary evidence of reliability and validity. *J Emotional Behav Disord* 14:118–125, 2006.
- Hwang J, Kim B, Kim Y, Kim T, Seo W, Shin D, Woo YJ, Yoo H, Lee JS, Lee JH, Lim MH, Chung YC, Jung CH, Yoo HK: Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder. *Hum Psychopharmacol* 28:600–607, 2013.

- Laugesen B, Lauritsen MB, Jørgensen R, Sørensen EE, Rasmussen P, Grønkjær M: Living with a child with attention deficit hyperactivity disorder: A systematic review. *Int J Evid Based Healthc* 14:150–165, 2016.
- Lee YC, Yang HJ, Chen VC, Hung WT, Teng MJ, Lin CH, Gossop M: Meta-analysis of quality of life in children and adolescents with ADHD: By both parent proxy-report and child self-report using PedsQL™. *Res Dev Disabil* 51–52:160–172, 2016.
- Matthijssen A-FM, Dietrich A, Bierens M, Deters RK, van de Loo-Neus GHH, van den Hoofdakker BJ, Buitelaar JK, Hoekstra PJ: Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: A randomized placebo-controlled discontinuation study. *Am J Psychiatry* 176:754–762, 2019.
- Mulraney M, Giallo R, Sciberras E, Lycett K, Mensah F, Coghill D: ADHD symptoms and quality of life across a 12-month period in children with ADHD: A longitudinal study. *J Atten Disord* 2017. <https://doi.org/10.1177/1087054717707046>
- NICE Guideline. Attention Deficit Hyperactivity Disorder: Diagnosis and Management. London: National Institute for Health and Care Excellence (UK); 2018.
- Poulton AS, Melzer E, Tait PR, Garnett SP, Cowell CT, Baur LA, Clarke S: Growth and pubertal development of adolescent boys on stimulant medication for attention deficit hyperactivity disorder. *Med J Aust* 198:29–32, 2013.
- Pringsheim T, Hirsch L, Gardner D, Gorman DA: The pharmacological management of oppositional behaviour, conduct problems, and Aggression in children and adolescents with Attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. *Can J Psychiatry* 60:52–61, 2015.
- Ravens-Sieberer AU, Bullinger M: Assessing health-related quality of life in chronically ill children with the German KINDL: First psychometric and content analytical results assessing health-related quality of life in chronically ill children with the German KINDL: First psychometric. *Qual Life Res* 7:399–407, 1998.
- Ravens-Sieberer U, Bullinger M: KINDL-R Questionnaire for Measuring Health-Related Quality of Life in Children and Adolescents Revised Version Manual. 2000. <https://www.kindl.org/english/manual/> Accessed December 16, 2019.
- Ros R, Graziano PA: Social functioning in children with or at risk for attention deficit/hyperactivity disorder: A meta-analytic review. *J Clin Child Adolesc Psychol* 47:213–235, 2018.
- Swanson JM. Debate: Are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? (Against). *J Am Acad Child Adolesc Psychiatry* 58:936–938, 2019.
- Van Widenfelt BM, Goedhart AW, Treffers PDA, Goodman R: Dutch version of the strengths and difficulties questionnaire (SDQ). *Eur Child Adolesc Psychiatry* 12:281–289, 2003.
- Zetterqvist J, Asherson P, Halldner L, Långström N, Larsson H: Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: Total population study of trends and discontinuation patterns 2006–2009. *Acta Psychiatr Scand* 128:70–77, 2013.
- Zhang S, Faries DE, Vowles M, Michelson D: ADHD Rating Scale IV: Psychometric properties from a multinational study as a clinician-administered instrument. *Int J Methods Psychiatr Res* 14: 186–201, 2005.

Address correspondence to:
Anne-Flore M. Matthijssen, MSc
Department of Child and Adolescent Psychiatry
University of Groningen, University Medical
Center Groningen (Accare)
Lubeckweg 2
9723 HE
Groningen
The Netherlands

E-mail: a.f.m.matthijssen@umcg.nl